Allarity Therapeutics shares fall 2.38% intraday after announcing a new licensing agreement with a non-disclosed EU-based biotechnology company.

Allarity Therapeutics, Inc. declined 2.38% intraday, with the company announcing a new commercial agreement with a non-disclosed EU-based biotechnology company. The agreement provides the partner with a non-exclusive global license to a range of selected proprietary Allarity DRP® algorithms in breast cancer, alongside laboratory services from Allarity’s Medical Laboratory in Denmark.